Tuberculosis remains a threat to global health, killing ~2 million people every year. The causative agent of tuberculosis, Mycobacterium tuberculosis, is thought to infect one-third of the world's population, sickening ~10 million people a year. Despite efforts to simplify treatment strategies, tuberculosis still requires months of multi-drug therapy to cure. Our research focuses on designing optimized therapies for TB using cell biology and engineering approaches. Our lab is a multidisciplinary research team, integrating quantitative measurement with computational modeling and analysis to create intuitive descriptions of complex cell biology. We focus our studies on (1) characterizing single-cell determinants of mycobacterial drug tolerance, (2) understanding how growth heterogeneity is controlled, and (3) engineering combination therapy.
Doctor of Philosophy, Massachusetts Institute of Technology, USA, 2008
Bachelor of Science, University of Arizona, USA, 2002